Abstract
Twenty-three patients with surgically verified unresectable hepatocellular carcinoma (HCC) have been treated by intrahepatic arterial administration of131I-labeled anti-HCC monoclonal antibody (Hepama-1) combined with hepatic artery ligation. Radioimmunoimaging demonstrated that the median tumor/liver ratio was 2.1 (1.1–3.6) at day 5. A decline in α-fetoprotein level and shrinkage of tumor were observed in 75% (12/16) and 78% (18/23) of patients respectively. Sequential resection was done in 11 patients (48%) after treatment. The surgical specimens revealed massive necrosis of tumor, but residual cancer cells were found at the edge of the specimens. Anti-antibody was determined in 43% (10/23) of patients 2–4 weeks after the administration of131I-Hepama-1 mAb. No marked toxic effects were noted. It is suggested that131I-Hepama-1 mAb might be of value as one of the multimodality treatments for unresectable HCC.
Key words: Radioimmunotherapy, Monoclonal antibody, Hepatocellular carcinoma, Radioimmunoimaging
References
- Blottiere HM, Steplewski Z, Herlyn D, Douillard JY (1991) Human anti-murine immunoglobulin responses and immune functions in cancer patients receiving murine monoclonal antibody therapy. Hum Antibodies Hybridomas 2:16–25 [PubMed] [Google Scholar]
- Blumenthal RD, Sharkey RM, Kashi R, Goldenberg DM (1991) Suppression of tumor vascular activity by radioantibody therapy: implications for multiple cycle treatments. Sel Cancer Ther 7:9–16 [DOI] [PubMed] [Google Scholar]
- Fan Z, Tang ZY, Liu KD, Zhou D, Lu JZ, Yuan AN, Zhao HY (1992) Radioiodinated anti-hepatocellular carcinoma (HCC) ferritin: targeting therapy, tumor imaging and anti-antibody response in HCC patients with hepatic arterial infusion. J Cancer Res Clin Oncol 118:371–376 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Muto MG, Finkler NJ, Kassis AI, Lepisto EM, Knapp RC (1990) Human anti-murine antibody responses in ovarian cancer patients undergoing radioimmunotherapy with the murine monoclonal antibody OD-125. Gynccol Oncol 38:244–248 [DOI] [PubMed] [Google Scholar]
- Oi VT, Herzenbere LA (1980) Immunoglobulin producing hybrid cell lines. In: Mishell BB, Shiigi SM (eds) Selected methods in cellular immulogy. Freman, San Francisco, pp 351–372 [Google Scholar]
- Pressman D, Day ED, Blau M (1957) The use of paired labeling in the determination of tumor-localizing antibodies. Cancer Res 17:845–850 [PubMed] [Google Scholar]
- Tang ZY, Liu KD, Bao YM, Lu JZ, Qian F, Yuan AN, Zhao HY (1990) Radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma with reference to second-look resection. Cancer 65:211–215 [DOI] [PubMed] [Google Scholar]
- Tang ZY, Yu YQ, Zhou XD, Ma ZC, Lu JZ, Liu KD, Lin ZY, Yang BH, Fan Z, Hou Z (1991) Cytoreduction and sequential resection: a hope for unresectable primary liver cancer. J Surg Oncol 47:27–31 [DOI] [PubMed] [Google Scholar]
- Vadhan-Raj S, Cordon-Cardo C, Carswell E, Minrzer D, Dantis L, Duteau C, Templetton MA, Oettgen HF, Old LJ, Houghton AN (1988) Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol 6:1636–1648 [DOI] [PubMed] [Google Scholar]
- Xie H, Yang ZH, Chen RM, Yao Z, Wang BM, Guo SY, Yan ZF (1985) Two mouse hybridomas secreting monoclonal antibodies against human liver carcinoma and their antibody specificity (in Chinese). Acta Biol Exp Sin 18:363–373 [PubMed] [Google Scholar]
- Yang NC, Leichner PK, Fishman EK, Siegelman SS, Frenkel TL, Wallace JR, Loudenslager DM, Hawkins WG, Order SE (1986) CT volumetrics of primary liver cancers. J Comput Assist Tomogr 10:621–628 [DOI] [PubMed] [Google Scholar]
- Zhang YJ, Tang ZY, Xie H, Yao Z, Yuan AN, Zhao HY, Lu JZ (1991) Imaging and therapy of human hepatocellular carcinoma with radiolabeled monoclonal antibody. J Exp Clin Cancer Res 10:243–251 [Google Scholar]